Articles tagged with Flu Vaccines
A study found that the high-dose flu vaccine significantly improves immune response to flu virus in frail, older residents of long-term care facilities. The vaccine provided superior protection against laboratory-confirmed influenza illness compared to the standard vaccine.
A study found that genetic variants in the IL-28B gene affect influenza vaccine responses. Individuals with at least one copy of the minor allele were more likely to achieve seroconversion after vaccination, particularly those on high doses of immune-suppressive drugs. Blocking the IL-28B receptor may boost the antibody response to flu...
A study found that seasonal flu vaccines protect against multiple flu strains, including those not included in vaccine formulations. The researchers also discovered that exposure to birds can elicit immune responses to avian influenza viruses in humans.
A University of Florida study found that vaccinating school-aged children from flu can protect other age groups, including non-school-aged residents, with significant reductions in influenza-like illness rates. This effect is profound, both on students and the community.
A study found that seasonal flu vaccines can induce strong immune responses against multiple flu virus subtypes, including some not included in vaccine formulations. This could provide protection against emerging pandemic strains from avian populations.
A Dartmouth/Univ. of Exeter study found that correcting myths about the flu vaccine did not effectively promote immunization among vaccine skeptics, and in some cases even reduced intention to vaccinate among those with high concerns about side effects.
A systematic review found that premature birth, neurological disorders, and multiple medical conditions significantly increase the risk of hospitalization in children with influenza. The study highlights the need for clearer guidelines on which children should be prioritized for seasonal flu vaccination.
A team of researchers has discovered that 'back boosting' the immune system by pre-emptively vaccinating against likely future strains of the influenza virus can significantly improve vaccine effectiveness. This approach would allow for more targeted and effective vaccination campaigns, potentially saving millions of lives worldwide.
The Liverpool School of Tropical Medicine has been awarded two substantial grants to further develop and utilise its Experimental Human Pneumococcal Carriage (EHPC) model. The first grant, worth $2.5 million, will investigate whether a nasal spray flu vaccine alters pneumococcal carriage.
A University of Adelaide-led project has developed a new test that can identify vaccinated birds with live H5N1 virus, preventing the spread of emerging strains. This breakthrough could help track and control the highly contagious avian influenza virus.
A new study reveals how flu vaccines prevent heart attacks by stimulating the immune system to produce antibodies that protect the heart. The research identifies a protein called BKB2R as the key mechanism behind this protective effect, and suggests it could be harnessed to develop a vaccine against heart disease.
Researchers at The Wistar Institute identified a new viral mutation that may explain why middle-aged adults were disproportionately affected by the H1N1 virus in 2013-2014. The study suggests that updating seasonal influenza vaccines with new viral strains could be crucial to protect this population.
Researchers will screen tens of thousands of chemical molecules to identify effective adjuvants for vaccines against infectious diseases. The project aims to develop novel applications for enhancing the immune response against Ebola virus, HIV, and other virus infections.
A new vaccine has been developed to treat a non-inherited autoimmune form of muscle weakness, with the researchers finding it effective in reversing the disease in rats. The vaccine targets immune cells that recognize and target a self protein, marking them for death.
A large clinical trial found that an H7N9 flu vaccine mixed with an adjuvant provided a protective immune response in 59% of participants. The addition of the adjuvant enhanced the effectiveness of the vaccine, even at lower dosages.
Research finds that a vaccine protecting against an old avian flu strain primes the immune system for a rapid response when a new vaccine is given a year later. Combining this with an adjuvant, a lower dose of the new vaccine works better in triggering an immune response than a stronger dose without it.
A new experimental vaccine against H7N9 avian influenza prompted immune responses in 59% of volunteers who received two injections with an adjuvant booster. Without the adjuvant, immune responses were minimal regardless of vaccine dosage.
Researchers examined new vaccination strategies to combat avian flu, finding that MF59 adjuvant improves immunogenicity and enhances efficacy. The studies also showed that prior exposure to a related antigen can lead to increased antibody responses to subsequent vaccinations.
The National Institute of Allergy and Infectious Diseases has awarded seven research contracts to discover novel vaccine adjuvants that safely boost immune responses. The goal is to improve current vaccines, extend the vaccine supply, or enhance efficacy in people with immature or weakened immune systems.
A flu shot is crucial for pregnant women to prevent serious illness and protect their babies from influenza. Vaccinated moms also have a lower risk of flu-related hospitalizations for chronic asthma, heart conditions, diabetes, and other health issues.
Researchers found that antibiotic treatment before vaccination impaired antibody responses in mice, while gut bacteria played a crucial role. The study's findings suggest that the microbiome could be harnessed to modulate vaccine efficacy and may explain variations in vaccine responses globally.
A new study reveals that gut microbes play a vital role in stimulating protective immune responses to the seasonal flu vaccine. Researchers found that mice with altered gut microbiota showed reduced antibody responses to vaccination, highlighting the importance of gut microbes in vaccine efficacy.
Racial and ethnic minorities are less likely to get vaccinated against flu due to missed opportunities by healthcare professionals. Offering flu shots more frequently could increase adult vaccination rates to 50% or above for all groups.
A statewide survey in Oregon found that most doctors recommend flu vaccine to healthy pregnant patients, but only half of American women receive the vaccine while pregnant. Doctors who see more pregnant patients or are younger are more likely to recommend vaccination.
A Vanderbilt-led study published in the New England Journal of Medicine found that the high-dose flu vaccine is 24% more effective than the standard-dose vaccine in protecting persons ages 65 and over against influenza illness. The study, which enrolled 31,989 participants, showed that the high-dose trivalent vaccine induces significan...
Karl Klose, a UTSA microbiologist, has received a $1 million contract from the US Department of Defense to develop a vaccine against tularemia. The bacteria can be deadly and has been developed as a bioweapon by several countries.
A private South African health plan increased patient use of preventive care services like mammograms and influenza vaccines through a novel retail incentive program. The program offered discounts on retail goods and travel for participants who used preventive services, resulting in a 5% increase in uptake.
A California-based study reveals a strong connection between hospital healthcare personnel influenza vaccination and the rate of influenza-like illnesses in surrounding communities. For every 15 vaccinated healthcare workers, one fewer case of flu is reported in the community.
Vaccination rates among healthcare workers are less than 50%, highlighting the need for policies that balance individual rights with public health. Mandatory flu vaccinations can benefit patient health, but must comply with employment law, provincial human rights codes, and the Canadian Charter of Rights and Freedoms.
School-based flu vaccine programs face financial challenges due to low reimbursement rates from third-party payers. Despite parental support for the program, billing and reimbursement issues pose significant problems for administrators.
Researchers at the University of Texas Medical Branch are working on a universal flu vaccine that could eliminate the need for annual flu shots. With a $4.4 million grant, they plan to test a vaccine containing antigens from A and B strains of influenza, aiming for approval within five years.
A new study suggests that self-administration of the flu vaccine via a microneedle patch could be feasible and increase vaccination rates. The study found that nearly all participants were able to accurately apply the patches, with significant increases in willingness to receive the vaccine.
Researchers developed a predictive fitness model for influenza, predicting optimal viral strain combinations for vaccines. The model considers innovation and conservation of viruses, providing insights into the complexity of influenza evolution.
A nationwide study in Denmark found that receiving the MMR vaccine on schedule was associated with a lower rate of hospital admissions for any infections, particularly lower respiratory tract infections. The study suggests that timely vaccination averted many hospital admissions between 16 and 24 months.
A study of 55 patients treated for flu at Duke University Hospital found that unvaccinated young adults had severe cases and required intensive treatment. The findings highlight the importance of vaccination in reducing severity and preventing costly hospitalizations.
Researchers at Scripps Research Institute developed a new method to design artificial proteins that can stimulate the production of virus-neutralizing antibodies. The approach was tested on a candidate vaccine against respiratory syncytial virus (RSV), showing promise in rhesus macaques.
A study by the University of Colorado School of Medicine found that only 62-65% of adults aged 65+ received pneumococcal or influenza vaccines, highlighting a growing public health concern. The study suggests using Immunization Information Systems to improve vaccination rates and address financial barriers.
A new study published in Diabetologia confirms that working-age adults with diabetes are at a higher risk of influenza compared to non-diabetic individuals. The research suggests that vaccinating this group could be cost-effective and mitigate healthcare costs associated with flu-related hospitalizations.
Researchers found that a new adjuvant improved flu vaccine effectiveness in mice and showed promise for the elderly. The study also highlighted the importance of characterizing immune responses following intra-nasal vaccinations, particularly with novel adjuvants.
A study by Columbia University's Mailman School of Public Health found that sending text messages to low-income obstetric patients resulted in a significant increase in influenza vaccination rates. Women who received the messages were 30% more likely to be vaccinated, with a subgroup showing a 61.9% vaccination rate.
A study found that simultaneous administration of these vaccines increases the risk of fever in young children, with about a third experiencing a fever of 100.4 F (38 C) or higher on the day of or day after vaccination.
A Stanford University School of Medicine study found that men with high testosterone levels have a weakened immune response to the flu vaccine, whereas women and men with lower testosterone levels have a stronger response. The study also discovered that testosterone interacts with genes in a way that dampens immune response.
A new study suggests that testosterone levels may affect the body's response to vaccines, with men often experiencing weaker antibody responses than women. Researchers found that men with high levels of testosterone had suppressed immune responses, which could be linked to their sex-specific differences in infections and vaccinations.
Researchers at Emory Vaccine Center compared the molecular signatures induced by five different vaccines to predict vaccine effectiveness and stimulate immune responses. The study suggests that gene expression predictors are dependent on vaccine type, rather than universal.
Pretreating intradermal vaccination with near-infrared laser light improves vaccine effectiveness by increasing immune system activity and survival rates in a mouse model. The treatment also increases antibody production and dendritic cell concentrations, indicating a safe alternative to chemical adjuvants.
Researchers at Tufts University found that wolfberries can increase immune system activity and protect against the flu virus in older mice who received the flu vaccine. The study suggests potential benefits for humans as well, where age-related weakening of the immune system reduces vaccine effectiveness.
A new guideline recommends most immunocompromised patients receive annual influenza shots, while those with cancer or undergoing chemotherapy should not. The guideline aims to provide 'one-stop shopping' for clinicians caring for immunocompromised patients.
Researchers have identified that seasonal flu escapes immunity by making just a single amino acid substitution, occurring at seven specific places on its surface. This new understanding could lead to more effective flu vaccines.
Research suggests that northern China conduct annual vaccinations starting in October, while southernmost provinces vaccinate in February. The study aims to optimize the timing of future vaccination programs and provides a clear picture of influenza seasonally across China.
A University of Michigan study found that reminder letters sent to parents of children with chronic conditions increased vaccination rates. The Michigan Care Improvement Registry was used to identify high-risk kids and prompt vaccinations during the 2009-10 H1N1 pandemic.
Individuals with a known gelatin allergy can experience mild to severe reactions from the flu shot, including hives, sneezing, and difficulty breathing. Precautions should be taken when receiving the vaccine, such as having a board-certified allergist administer it.
Scientists at Arizona State University have developed a microchip-based technology called immunosignature diagnosis that can rapidly measure an individual's vaccine response. This innovation has the potential to significantly reduce the costs and timeframes of vaccine testing, allowing for more effective vaccines to be identified.
A meta-analysis found that receiving an influenza vaccination was associated with a lower risk of major adverse cardiovascular events. The greatest treatment effect was seen among patients with recent acute coronary syndrome (ACS), such as heart attack or unstable angina.
New research led by Dr. Jacob Udell found that the flu vaccine reduces the risk of heart attack or stroke by over 50% among those who have had a heart attack. The study also suggests that the vaccine's heart-protective effects may be even greater among those who receive a more potent vaccine.
A study published in the Journal of the American Medical Association found that flu shots reduced the risk of heart attack or stroke by 36-55% among patients with a history of heart disease. The vaccine's protective effects were greater in those who received a more potent vaccine.
Researchers have discovered a novel way to generate antibodies that target multiple flu viruses, offering new hope for developing a single vaccine against all strains. The study used the immune suppressant rapamycin to shift the immune response and favor production of broadly specific antibodies.
A recent study found that high-risk travelers, including those with medical comorbidities and pregnant women, account for nearly 20 percent of patients using the Boston Area Travel Medicine Network. These travelers often visited destinations with malaria and typhoid risk, highlighting the need for pre-travel care.
A UK-based study found that expanding flu vaccination policies to include children aged 5-16 could significantly reduce the number of flu infections and deaths. The current policy targets adults over 65 and high-risk groups, which has shown success in reducing morbidity and mortality.
The National Institute of Allergy and Infectious Diseases has renewed a 10-year contract with the University of Maryland School of Medicine's Center for Vaccine Development, providing up to $135 million in annual funding. The center will conduct basic research, clinical studies, and vaccine development to combat existing and emerging i...
The NIH has awarded nine new contracts to strengthen the scope of its Vaccine and Treatment Evaluation Units, increasing funding from eight to nine institutions. The VTEUs will expand their ability to conduct research in domestic and international locations, including resource-poor settings.